Media stories about Tocagen (NASDAQ:TOCA) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tocagen earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0963616487138 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Tocagen to Present at Two Investor Conferences in November (finance.yahoo.com)
- Tocagen Inc (TOCA) Issues Quarterly Earnings Results (americanbankingnews.com)
- Tocagen Reports Third Quarter 2017 Financial and Business Results (finance.yahoo.com)
- Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences (finance.yahoo.com)
Several analysts have weighed in on TOCA shares. Zacks Investment Research raised Tocagen from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Stifel Nicolaus reiterated a “buy” rating and set a $24.00 price objective on shares of Tocagen in a research report on Tuesday, July 25th.
Tocagen (NASDAQ TOCA) traded down $0.13 on Monday, reaching $10.37. The company had a trading volume of 140,400 shares, compared to its average volume of 318,568. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03. Tocagen has a fifty-two week low of $8.60 and a fifty-two week high of $17.95.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. research analysts forecast that Tocagen will post -2.88 earnings per share for the current fiscal year.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.